FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * GOWER JAMES M				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 08/20/2004							//Year)		X Officer (give title below) Other (specify below) CEO & Board Chairman				
SOUTH	SAN FRA	(Street) NCISCO, C	A 94080	4. If <i>i</i>	Amendr	nent,	Date	Origin	nal File	ed(Month	n/Day/Year)		_X_ Form fil	ed by One Repo	Group Filing orting Person one Reporting	• • •	ble Line)
(City	(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3) Da		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)					f (D) Benefici		ally Owned Following I Transaction(s)		\ /	Beneficial Ownership		
							С	ode	V.	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Commor	Stock		08/20/2004					J		380 (1	<u>)</u> A	\$ 0	125,628	(2)		D	
			Table II -					quire	the fo	orm dis	splays a	curre: eficial	ntly valid		spond unle trol numbe		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Day Year) any	4. Transaction Code Year) (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Und Secu	itle and ount of erlying urities tr. 3 and	Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Beneficia Ownershi (Instr. 4)		
									Date		Expiration Date	1 Title	Amount or Number				

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GOWER JAMES M RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		CEO & Board Chairman				

Signatures

/s/ James H. Welch (Attorney-in-Fact)	08/20/2004
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The reporting person received the shares from a distribution by Alta Embarcadero BioPharma Partners II, LLC to its members.
- (2) Includes 542 shares of common stock acquired on 6/30/04 under the 2000 Employee Stock Purchase Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.